Document is current
Any future updates will be listed below
-
Authors
Centeno, Christopher J.
Berger, Dustin R.
Pitts, John
Markle, Jason
Pelle, Andrew J.
Murphy, Matthew
Dodson, Ehren
- License Information
-
More Information
Article History
Received: 13 January 2025
Accepted: 22 August 2025
First Online: 30 September 2025
Declarations
:
: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the International Cellular Medicine Society Institutional Review Board (OHRP #IRB00002637, Approval number: ICMS-2013-0015, date: 04/22/2013). All patients signed informed consent before participating in the trial.
: Not applicable.
: One or more of the authors has declared a potential conflict of interest. DRB, MM, and ED are employed by Regenexx, LLC. CJC is a shareholder, patent holder, and Chief Medical Officer of Regenexx, LLC and an owner of the Centeno-Schultz Clinic. JP, JM, and AJP are employed by the Centeno-Schultz Clinic.
